OptimizeRx Corporation (OPRX) Financial Statements
OptimizeRx Corporation (OPRX) reported trailing twelve-month revenue of $98.7M (down 5.8% year on year) and net income of $4.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $18.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OPRXOptimizeRx CorporationFollow OPRX — free
—
Price chart with a free account
- Market cap
- 172.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1 | 2.0 | 4.7 | 6.5 | 7.2 | 7.8 | 12.1 | 21.2 | 24.6 | 43.3 | 61.3 | 62.5 | 71.5 | 92.1 | 109.4 | 98.7 | |
| Gross profit | — | — | 2.8 | 3.3 | 3.6 | 4.3 | 6.0 | 12.2 | 15.4 | 24.1 | 35.6 | 39.0 | 42.9 | 59.4 | 73.6 | 72.2 | |
| Research & development | — | — | — | — | — | — | — | — | 1.6 | 0.0 | — | — | — | 0.0 | 0.0 | — | |
| Operating income | -1.5 | -0.5 | -0.3 | -1.0 | -0.6 | -1.6 | -2.1 | 0.2 | -3.7 | -2.1 | 0.4 | -12.3 | -26.4 | -13.7 | 11.7 | 10.9 | |
| Pre-tax income | — | — | -0.3 | -1.0 | -0.6 | -1.5 | -2.1 | 0.2 | -4.0 | -2.2 | 0.4 | -11.4 | -25.2 | -19.4 | 7.0 | 6.8 | |
| Income tax | — | — | — | 0.0 | 0.0 | — | — | — | -0.9 | — | — | — | -7.6 | 0.7 | 1.8 | 2.2 | |
| Net income | -2.1 | -0.5 | -0.3 | -1.0 | -0.6 | -1.5 | -2.1 | 0.2 | -3.1 | -2.2 | 0.4 | -11.4 | -17.6 | -20.1 | 5.1 | 4.6 | |
| Diluted EPS ($) | — | — | 0.01 | -0.04 | — | -0.05 | -0.07 | 0.02 | -0.23 | -0.15 | 0.02 | -0.64 | -1.03 | -1.10 | 0.27 | 0.23 | |
| Diluted shares (mn) | — | — | — | 24.0 | — | — | 9.8 | 11.9 | 13.4 | 14.8 | 17.7 | 17.8 | 17.1 | 18.3 | 19.0 | — |
USD millions · SEC XBRL
OptimizeRx Corporation — questions
- What is OptimizeRx Corporation's revenue?
- $98.7M over the twelve months to 2026-06-30, down 5.8% year on year, from its 10-Q and 10-K filings.
- What is OptimizeRx Corporation's net income?
- $4.6M over the twelve months to 2026-06-30.
- What is OptimizeRx Corporation's free cash flow?
- $18.3M over the twelve months to 2026-06-30.
- What are OptimizeRx Corporation's diluted earnings per share?
- $0.23 over the twelve months to 2026-06-30.
Every figure on this page comes from OptimizeRx Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.